Wegovy vs Mounjaro vs Zepbound in Bangkok: 2026 prices, supply, and which to pick
Side-by-side comparison of the three branded GLP-1 pens available in Bangkok in May 2026. Per-month USD pricing at premium hospitals and mid-tier clinics, supply state per medication, and the picking question once cost is on the table.
Three branded GLP-1 pens are available through Bangkok's private clinic and hospital network in May 2026: Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide for the obesity indication, distinct branding). Different active molecules in two cases, different brand positioning across all three, and meaningfully different price + supply profiles per channel.
This post is the side-by-side. What's actually in stock, what each costs at the premium-hospital tier and the mid-tier clinic tier, and the picking question once you have the numbers.
What each one is
- Wegovy · semaglutide branded for chronic weight management. Same molecule as Ozempic (which is branded for type-2 diabetes). 2.4mg once-weekly maintenance dose. STEP trials show ~15% body-weight reduction at 68 weeks.
- Mounjaro · tirzepatide branded for type-2 diabetes. Dual GIP and GLP-1 agonist. Doses from 2.5mg to 15mg once-weekly. Eli Lilly product.
- Zepbound · tirzepatide branded for chronic weight management. Same molecule and dose ladder as Mounjaro, different label and indication. Eli Lilly product. SURMOUNT trials show ~20.9% body-weight reduction at 72 weeks at the 15mg dose.
In Thailand, both Mounjaro and Zepbound carry tirzepatide. Clinical-effect-wise they are interchangeable. Brand positioning differs · Mounjaro is the long-established name and the one most clinics stock; Zepbound launched later in the global market and Thai distribution has been thinner. The Wegovy + Mounjaro pair is the practical decision most Bangkok-resident expats face.
What's actually in stock, May 2026
| Medication | Premium hospitals | Mid-tier clinics |
|---|
If a clinic does not stock the specific brand you ask for, the substitution they offer reveals their channel posture. A premium hospital that says "we have Mounjaro instead of Zepbound, same molecule" is being honest. A clinic that says "we have something equivalent" without naming what is signaling channel-clarity below where we route.
Per-month USD pricing, May 2026
Premium hospitals run 1.4 to 2x the mid-tier on the same dose. Insurance coverage varies (international plans more often cover obesity-indication pens than diabetes-indication, and BNH is the most insurance-friendly of the BKK premium tier).
| Medication | Premium hospital | Mid-tier clinic |
|---|
Numbers normalized from the public price pages of the Bangkok premium-hospital comparison vendors and the mid-tier clinics in our /vendor catalog. Consult fees at premium hospitals add USD 30 to 150 per visit; mid-tier clinics typically include the consult.
The picking question
Cost is one signal. The two other things to weigh:
Tolerability. Tirzepatide (Mounjaro/Zepbound) has more efficacy than semaglutide (Wegovy/Ozempic) but also more GI side effect surface area at high doses. Patients new to the GLP-1 class often tolerate Wegovy 2.4mg better than Mounjaro 10mg+ because the dose-step is shallower. The matchmaker accounts for urgency and budget signals · users picking "ready" + "full optimization" usually route to Mounjaro at higher doses; users picking "researched" + "meaningful" usually route to Wegovy or Mounjaro at lower doses.
Long-term continuity. SURMOUNT-4 + STEP-5 both show that stopping the drug returns weight in most patients. If you anticipate this is a long-term protocol, the per-month cost compounded over 12 to 36 months matters more than the cheaper-this-month answer. Mid-tier clinics with a 12-month relationship often beat premium hospitals on lifetime cost despite the same per-pen price.
Cross-region resupply. If you split time between Bangkok and another expat market, the medication that is easiest to refill at your other locations matters. Mounjaro is the most globally-distributed of the three; Wegovy is widely available across EU and UK; Zepbound is currently US-primary. The Bangkok-hop playbook covers the cross-border math for expats elsewhere in SE Asia.
What we recommend
For most Bangkok-resident expats new to the class with a body-weight reduction goal: start with Mounjaro at the mid-tier clinic, escalate slowly through the dose ladder, plateau at whichever dose gets you the result with tolerable side effects. Wegovy is the right pick if you are GLP-1-class-naive and want a shallower dose ramp. Zepbound is the right pick if you specifically want the obesity-indication label (matters for some insurance plans + some employer benefits in the US, less so in Thailand).
The matchmaker at /quiz routes by your goal cluster, region, and budget. The recommended vendor will have the 11-signal rubric breakdown on its scorecard so you can read the per-signal context before transacting. The premium-hospital comparison at /blog/bangkok-premium-hospitals-glp1-2026 goes deeper on Bumrungrad vs Samitivej vs BNH vs BDMS Wellness if your route is the JCI-anchored tier.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.
After the FDA crackdown: the state of US compounded GLP-1 in May 2026
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
Bali GLP-1 supply tactical update May 2026: what's actually in stock at each clinic this month
BPOM intermittency means the existing Bali buyers guide gets stale fast. This is the May 2026 supply-state tactical · per-clinic Mounjaro and Ozempic stocking, the most-current expat-routable picks, and the Bangkok-hop fallback when the nomad-clinic layer has gaps.
The Bangkok GLP-1 hop: a practical playbook for expats in Bali, Singapore, Hanoi, HCMC, KL, Manila
Bangkok is the regional anchor for legitimately-supplied tirzepatide and semaglutide in Southeast Asia. Flight matrices, clinic-relationship cadence, cold-chain transit, customs personal-use rules per origin country, and the four-versus-twelve-week supply math.